328 related articles for article (PubMed ID: 37460938)
1. Interrogating colorectal cancer metastasis to liver: a search for clinically viable compounds and mechanistic insights in colorectal cancer Patient Derived Organoids.
Cioce M; Fumagalli MR; Donzelli S; Goeman F; Canu V; Rutigliano D; Orlandi G; Sacconi A; Pulito C; Palcau AC; Fanciulli M; Morrone A; Diodoro MG; Caricato M; Crescenzi A; Verri M; Fazio VM; Zapperi S; Levrero M; Strano S; Grazi GL; La Porta C; Blandino G
J Exp Clin Cancer Res; 2023 Jul; 42(1):170. PubMed ID: 37460938
[TBL] [Abstract][Full Text] [Related]
2. Organoids as a biomarker for personalized treatment in metastatic colorectal cancer: drug screen optimization and correlation with patient response.
Smabers LP; Wensink E; Verissimo CS; Koedoot E; Pitsa KC; Huismans MA; Higuera Barón C; Doorn M; Valkenburg-van Iersel LB; Cirkel GA; Brousali A; Overmeer R; Koopman M; Braat MN; Penning de Vries B; Elias SG; Vries RG; Kranenburg O; Boj SF; Roodhart JM
J Exp Clin Cancer Res; 2024 Feb; 43(1):61. PubMed ID: 38414064
[TBL] [Abstract][Full Text] [Related]
3. Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity.
Bruun J; Kryeziu K; Eide PW; Moosavi SH; Eilertsen IA; Langerud J; Røsok B; Totland MZ; Brunsell TH; Pellinen T; Saarela J; Bergsland CH; Palmer HG; Brudvik KW; Guren T; Dienstmann R; Guren MG; Nesbakken A; Bjørnbeth BA; Sveen A; Lothe RA
Clin Cancer Res; 2020 Aug; 26(15):4107-4119. PubMed ID: 32299813
[TBL] [Abstract][Full Text] [Related]
4. Disease Modeling on Tumor Organoids Implicates AURKA as a Therapeutic Target in Liver Metastatic Colorectal Cancer.
Boos SL; Loevenich LP; Vosberg S; Engleitner T; Öllinger R; Kumbrink J; Rokavec M; Michl M; Greif PA; Jung A; Hermeking H; Neumann J; Kirchner T; Rad R; Jung P
Cell Mol Gastroenterol Hepatol; 2022; 13(2):517-540. PubMed ID: 34700030
[TBL] [Abstract][Full Text] [Related]
5. "Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction".
Papaccio F; García-Mico B; Gimeno-Valiente F; Cabeza-Segura M; Gambardella V; Gutiérrez-Bravo MF; Alfaro-Cervelló C; Martinez-Ciarpaglini C; Rentero-Garrido P; Zúñiga-Trejos S; Carbonell-Asins JA; Fleitas T; Roselló S; Huerta M; Sánchez Del Pino MM; Sabater L; Roda D; Tarazona N; Cervantes A; Castillo J
J Exp Clin Cancer Res; 2023 Jan; 42(1):8. PubMed ID: 36604765
[TBL] [Abstract][Full Text] [Related]
6. Patient-Derived Organoid Serves as a Platform for Personalized Chemotherapy in Advanced Colorectal Cancer Patients.
Geevimaan K; Guo JY; Shen CN; Jiang JK; Fann CSJ; Hwang MJ; Shui JW; Lin HT; Wang MJ; Shih HC; Li AF; Chang SC; Yang SH; Chen JY
Front Oncol; 2022; 12():883437. PubMed ID: 35719949
[TBL] [Abstract][Full Text] [Related]
7. Comparative Analysis of Patient-Matched PDOs Revealed a Reduction in OLFM4-Associated Clusters in Metastatic Lesions in Colorectal Cancer.
Okamoto T; duVerle D; Yaginuma K; Natsume Y; Yamanaka H; Kusama D; Fukuda M; Yamamoto M; Perraudeau F; Srivastava U; Kashima Y; Suzuki A; Kuze Y; Takahashi Y; Ueno M; Sakai Y; Noda T; Tsuda K; Suzuki Y; Nagayama S; Yao R
Stem Cell Reports; 2021 Apr; 16(4):954-967. PubMed ID: 33711267
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer liver metastases organoids retain characteristics of original tumor and acquire chemotherapy resistance.
Buzzelli JN; Ouaret D; Brown G; Allen PD; Muschel RJ
Stem Cell Res; 2018 Mar; 27():109-120. PubMed ID: 29414601
[TBL] [Abstract][Full Text] [Related]
9. Implementing patient derived organoids in functional precision medicine for patients with advanced colorectal cancer.
Cartry J; Bedja S; Boilève A; Mathieu JRR; Gontran E; Annereau M; Job B; Mouawia A; Mathias P; De Baère T; Italiano A; Besse B; Sourrouille I; Gelli M; Bani MA; Dartigues P; Hollebecque A; Smolenschi C; Ducreux M; Malka D; Jaulin F
J Exp Clin Cancer Res; 2023 Oct; 42(1):281. PubMed ID: 37880806
[TBL] [Abstract][Full Text] [Related]
10. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
11. Patient-Derived Organoids from Colorectal Cancer with Paired Liver Metastasis Reveal Tumor Heterogeneity and Predict Response to Chemotherapy.
Mo S; Tang P; Luo W; Zhang L; Li Y; Hu X; Ma X; Chen Y; Bao Y; He X; Fu G; Xu X; Rao X; Li X; Guan R; Chen S; Deng Y; Lv T; Mu P; Zheng Q; Wang S; Liu F; Li Y; Sheng W; Huang D; Hu C; Gao J; Zhang Z; Cai S; Clevers H; Peng J; Hua G
Adv Sci (Weinh); 2022 Nov; 9(31):e2204097. PubMed ID: 36058001
[TBL] [Abstract][Full Text] [Related]
12. Platform combining statistical modeling and patient-derived organoids to facilitate personalized treatment of colorectal carcinoma.
Ramzy GM; Norkin M; Koessler T; Voirol L; Tihy M; Hany D; McKee T; Ris F; Buchs N; Docquier M; Toso C; Rubbia-Brandt L; Bakalli G; Guerrier S; Huelsken J; Nowak-Sliwinska P
J Exp Clin Cancer Res; 2023 Apr; 42(1):79. PubMed ID: 37013646
[TBL] [Abstract][Full Text] [Related]
13. Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer.
Hao M; Cao Z; Wang Z; Xin J; Kong B; Xu J; Zhang L; Chen P
ACS Biomater Sci Eng; 2022 Aug; 8(8):3515-3525. PubMed ID: 35696669
[TBL] [Abstract][Full Text] [Related]
14. Wnt-driven LARGE2 mediates laminin-adhesive O-glycosylation in human colonic epithelial cells and colorectal cancer.
Dietinger V; García de Durango CR; Wiechmann S; Boos SL; Michl M; Neumann J; Hermeking H; Kuster B; Jung P
Cell Commun Signal; 2020 Jun; 18(1):102. PubMed ID: 32586342
[TBL] [Abstract][Full Text] [Related]
15. Correlation between chemosensitivity and mRNA expression level of 5-fluorouracil-related metabolic enzymes during liver metastasis of colorectal cancer.
Okumura K; Shiomi H; Mekata E; Kaizuka M; Endo Y; Kurumi Y; Tani T
Oncol Rep; 2006 Apr; 15(4):875-82. PubMed ID: 16525674
[TBL] [Abstract][Full Text] [Related]
16. Colorectal cancer organoid models uncover oxaliplatin-resistant mechanisms at single cell resolution.
Chen G; Gong T; Wang Z; Wang Z; Lin X; Chen S; Sun C; Zhao W; Kong Y; Ai H; Yang H; Liu Y; Wu F; Kang J; Zhao S; Xiao X; Sun J; He A; Li Z
Cell Oncol (Dordr); 2022 Dec; 45(6):1155-1167. PubMed ID: 36136268
[TBL] [Abstract][Full Text] [Related]
17. Patient-derived organoids as a platform for drug screening in metastatic colorectal cancer.
He X; Jiang Y; Zhang L; Li Y; Hu X; Hua G; Cai S; Mo S; Peng J
Front Bioeng Biotechnol; 2023; 11():1190637. PubMed ID: 37284236
[No Abstract] [Full Text] [Related]
18. Lansoprazole inhibits the development of sessile serrated lesions by inducing G1 arrest via Skp2/p27 signaling pathway.
Kawaguchi T; Okamoto K; Fujimoto S; Bando M; Wada H; Miyamoto H; Sato Y; Muguruma N; Horimoto K; Takayama T
J Gastroenterol; 2024 Jan; 59(1):11-23. PubMed ID: 37989907
[TBL] [Abstract][Full Text] [Related]
19. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito R; Semiannikova M; Griffiths B; Khan K; Barber LJ; Woolston A; Spain G; von Loga K; Challoner B; Patel R; Ranes M; Swain A; Thomas J; Bryant A; Saffery C; Fotiadis N; Guettler S; Mansfield D; Melcher A; Powles T; Rao S; Watkins D; Chau I; Matthews N; Wallberg F; Starling N; Cunningham D; Gerlinger M
J Immunother Cancer; 2019 Apr; 7(1):101. PubMed ID: 30982469
[TBL] [Abstract][Full Text] [Related]
20. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
